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ABSTRACT
Background: Dipeptidyl peptidase-4 (DPP4) is an enzyme responsible for inactivating the hormone incretin, which potentiates insulin secretion and 
glucagon inhibition; inhibitors of DPP4 are used as therapeutic drugs for type-2 diabetes.
Objective: In this study, we evaluated potential DPP4 inhibitors from the Indonesian Medicinal Plants Database using an in silico approach.
Methods: A ligand-based pharmacophore model was used for screening the database using LigandScout 4.2. This model was validated using several 
parameters of enrichment metrics, including receiver operating characteristics, area under curve (AUC), and enrichment factor (EF). Hit compounds 
were also docked with DPP4 to calculate the free binding energy and analyze the interaction between the ligand and DPP4. In addition, bioavailability 
and medicinal chemistry predictions were performed for the hit compounds.
Results: The best pharmacophore model demonstrated AUC100% and EF1% values of 0.82 and 33.8, respectively. The pharmacophore features of the 
model included hydrogen bond donors, hydrogen bonds, hydrophobic interactions, and positive ionization areas. Based on our results of virtual 
screening and molecular docking, six hit compounds were ultimately identified, namely, L-noradrenaline, octopamine, Nb-demethylechitamine, alliin, 
isoalliin, and subaphylline.
Conclusion: Collectively, our findings indicate that subaphylline is the most promising compound for further studies, including in vitro and in vivo 
experiments and those focused on molecular dynamics and structural modification.
Keywords: Dipeptidyl peptidase-4, Virtual screening, Pharmacophore-based, Molecular docking, In silico, Diabetes.
INTRODUCTION
Dipeptidyl peptidase-4 (DPP4) has been identified as a potential new 
therapeutic target for reducing the rate of diabetes and its associated 
early mortality. DPP4 plays a role in glucose homeostasis by deactivating 
the incretin hormones glucose-dependent insulinotropic peptide and 
glucagon-like peptide-1 that potentiate insulin secretion from pancreatic 
β cells and inhibits glucagon secretion from pancreatic alpha cells [1,2]. 
However, these two hormones are short-lived because they are rapidly 
degraded by the DPP4 enzyme shortly after they are secreted. DPP4 
inhibitors prevent the action of the enzyme, resulting in increased levels 
of active incretin hormones in the body, which serves to increase the 
body’s ability to control blood glucose levels. However, DPP4 has an 
amino acid residue composition and active site pocket that are similar 
to other DPP isozymes [3]. Thus, there is the possibility of inhibiting 
other DPP4 isozymes with the use of non-selective DPP4 inhibitors. 
Based on a review by Drucker, non-selective DPP4 inhibitors can impact 
immune regulation, biological transplantation, cancer cell growth, and 
metastasis [2]. In addition, toxicity and tolerability studies with selective 
DPP4, DPP8, DPP9, and QPP inhibitors have revealed that DPP8/9 and 
QPP inhibitors produce toxicity in test animals, whereas selective DPP4 
inhibitors do not, suggesting that selectivity assessments of potential 
clinical candidates are essential for an optimal safety profile [4].
“Gliptin” is a DPP4 inhibitor that was chemically synthesized and can 
be categorized based on the similarity of the chemical scaffold and its 
binding mode. Various heterocyclic frameworks have been reported 
to have inhibitory activity against DPP4 [5,6]. Virtual screening with a 
pharmacophore approach is one method that can be used in search of 
potential new compounds as DPP4 inhibitors with different structural 
frameworks have been reported. Pharmacophores are the steric 
and electronic feature ensembles needed to ensure supramolecular 
interactions with optimal specific biological targets and trigger 
or inhibit their biological responses [7]. Three-dimensional (3D) 
pharmacophore modeling is a technique that describes the interaction 
of small molecular ligands with macromolecular targets. This approach 
is considered intuitive and has been increasingly successful in the 
discovery of computational medicine in recent years [8-10]. In this 
study, virtual screening was performed on the database of Indonesian 
herbal plants using a 3D pharmacophore approach to obtain hit 
compound candidates that can selectively inhibit DPP4 activity.
METHODS
Virtual screening
Two-dimensional structures (.mol) of the ligand candidates were 
obtained from the Indonesian Herbal Database (www.herbaldb.farmasi.
ui.ac.id) containing 1377 compounds. Structures were converted to 
one-dimensional (1D) structures (.smi) for screening purposes. The 
1D structures (.smi) of the active compound and “gliptin” with 547 
compounds were obtained from A Directory of Useful Decoys (DUD, www.
dude.docking.org) and PubChem (www.ncbi.nlm.nih.gov/pccompound) 
databases. The 1D structures (.smi) of the decoys were obtained from A 
DUD (www.dude.docking.org) that contains 40,944 compounds.
A ligand-based pharmacophore model was created using LigandScout 4.2. 
The active compounds were divided into two datasets, namely, 17 “gliptin” 
compounds used as the training set and 530 compounds used as the test 
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set. The training set data were used to build the pharmacophore model. 
The test set data for both the active and decoy compounds were converted 
into the.ldb format for screening processes to validate the pharmacophore 
models that were developed. The best pharmacophore model was selected 
by calculating several validation parameters, including receiver operating 
characteristics (ROC), area under curve (AUC), and enrichment factor 
(EF). Virtual screening was performed on the Indonesian Herbal Database 
with the best pharmacophores model using LigandScout 4.2.
Molecular docking
The 3D structure of the homo sapiens DPP4 protein macromolecule 
was obtained from the Protein Data Bank (http://www.rcsb.org/pdb) 
as 5T4B, which is the DPP4 homodimer (chain A and B) with 728 
amino acids, bound with the (34a) ligand (2-[(3R)-3-aminopiperidin-
1-yl]-3-(but-2-yn-1-yl)-5-[(4-methylquinazolin-2-yl)methyl]-3H-
imidazo[2,1-b]purin-4(5H)-one; 75N), N-acetyl-D-glucosamine and 
sodium ion, with a resolution value of 1.76 Å [11].
Hit compounds resulting from the in silico screening were docked into 
the crystal structure of DPP4 using Autodock4.2. The position of the 
(34a) ligand in the X-ray crystal structure was defined as the DPP4 
active site and determined using LigandScout. The center of the ligand 
coordinates X, Y, and Z were 37.6567, 50.0321, and 40.1088 angstroms, 
respectively. The original ligand (34a) was also redocked with the DPP4 
structure to verify the molecular docking procedure by measuring the 
root-mean-square deviation (RMSD) between the best pose obtained 
by docking and the X-ray crystal structure at <2.0 Å.
Bioavailability and medicinal chemistry predictions
We performed calculations related to various bioavailability and medicinal 
chemistry parameter predictions using SwissADME free web tools [12] 
(http://www.swissadme.ch). Various parameters were predicted, including 
physicochemical properties such as molecular weight (MW), count 
of specific atom types, molar refractivity (MR), polar surface area, 
lipophilicity (Log P), and solubility (Log S). These parameters were then 
interpreted in assessing the parameters of drug-likeness, lead-likeness, and 
pharmacokinetics. Other predictions, such as the tendency of a compound 
to become a substrate/non-substrate for glycoprotein permeability and 
its interaction with cytochrome P450, were also carried out to enrich the 
pharmacokinetic assessment of the compounds. Furthermore, potentially 
problematic fragments related to molecular accessibility, medicinal 
chemistry, and compound synthesis were also identified.
RESULTS
Virtual screening and validation
Pharmacophore model 9 was considered the best model and was 
chosen based on the ROC graph (Fig. 1) of the ten 3D pharmacophore 
models that were developed with AUC100% and EF1% values of 0.82 and 
33.8, respectively.
The best pharmacophore model for the entire gliptin contains a 
consensus of four basic pharmacophore features, including hydrogen 
bond donors (HBD; marked in red), hydrogen bond acceptors (HBA; 
marked in green), hydrophobic interactions (marked in yellow), and 
positive ionized (PI) areas (marked in blue).
Virtual screening was performed on the Indonesian Herbal Database 
with the best pharmacophores model using LigandScout 4.2. Based on 
the results of the in silico screening, 12 hit compounds were obtained, 
namely, l-noradrenaline, which had the highest pharmacophore-fit 
score of 48.37, followed by octopamine, miraxanthin-ii, miraxanthin-i, 
miraxanthin-v, mimosine, Nb-demethylechitamine, l-histidine, alliin, 
isoalliin, subaphylline, and l-theanine (Table 1). Overall, the hit 
compounds matched with three types of pharmacophore features: Two 
HBA (red), one HBD (green), and one PI area (blue).
Molecular docking
Differing from the results of in silico screening where l-noradrenaline 
had the highest feature pharmacophore-fit score, the compound with the 
best free binding energy (∆G value, in kcal/mol) in terms of molecular 
docking was subaphylline (−8.2), followed by Nb-demethylechitamine 
(−7.39), l-noradrenaline (−7.12), octopamine (−6.93), isoalliin (−6.81), 
alliin (−6.54), mimosine (−6.47), l-theanine (−6.03), miraxanthin-
ii (−4.93), miraxanthin-v (−5.70), miraxanthin-I (−5.57), l-histidine 
(−5.46), and miraxanthin-ii (−4.93) (Table 1).
Overall, at least nine compounds interacted with the residues in the DPP4 
active sites; these have been reported in previous studies [1,10-14], and 
eight of them have been predicted to be more selective toward DPP4 
because they have interactions with the S1’ subsite. The remaining 
three compounds with the lowest binding affinities (miraxanthin-i, ii, 
and v) do not appear to interact with the residues in the active sites of 
DPP4 (Table 2 and Fig. 2).
Bioavailability and medicinal chemistry predictions
Predictions were made for six hit compounds with interaction 
energy values <−6.50 kcal/mol and were suitable for interaction 
with the active site of DPP4. These compounds were subaphylline, 
Nb-demethylechitamine, l-noradrenaline, octopamine, isoalliin, and 
alliin. Overall, based on our prediction results, the six hit compounds 
had good oral bioavailability, were suitable for synthesis, and met the 
criteria of drug-likeness and lead-likeness (Table 3 and Fig. 4).
DISCUSSION
Virtual screening and molecular docking
The pharmacophore feature is a type of ligand-receptor interaction 
and includes HBD, HBA, positively and negatively charged groups, and 
hydrophobic regions [7]. The best pharmacophore model was built 
based on 17 gliptin compounds that have been previously reported. 
A pharmacophore model can have an AUC value between 0 (all inactive 
molecules first) and 1 (all active molecule first) an AUC value of 0.5 
means that the method performed like a random selection [15]. The 
best pharmacophore model had an AUC100% value of 0.82, which means 
the model is useful for virtual screening.
Virtual screening was performed on the Indonesian Herbal Database 
with the best pharmacophores model using LigandScout 4.2. As 
shown in Fig. 5, the best pharmacophore model for the entire 
gliptin contains a consensus of four basic pharmacophore features, 
including two HBD, one HBA, one hydrophobic interactions, and one 
Fig. 1: Receiver operating characteristics graph of the best 
pharmacophore model
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Table 1: Hit compounds from in silico screening using Ligandscout 4.2
Compound Two-dimensional structure Matching feature Pharmacophore-fit score ∆G* (kcal/mol) Ki* (µM)
L-noradrenaline 48.37 −7.12 6.00
Octopamine 48.07 −6.93 8.39
Miraxanthin-II 47.75 −4.93 244.82
Miraxanthin-I 46.90 −6.03 82.41
Miraxanthin-V 46.36 −5.70 66.80
Mimosine 46.02 −6.47 18.04
Nb-demethylechitamine 45.95 −7.39 3.83
L-histidine 45.71 −5.46 99.92
Alliin 45.61 −6.54 16.02
Isoalliin 45.39 −6.81 10.15
Subaphylline 45.29 −8.20 0.98
L-theanine 45.11 −6.03 38.30
*Calculated from the molecular docking state by Autodock4
PI areas. 12 hit compounds were obtained, namely, l-noradrenaline, 
octopamine, miraxanthin-ii, miraxanthin-i, miraxanthin-v, mimosine, 
Nb-demethylechitamine, l-histidine, alliin, isoalliin, subaphylline, and 
l-theanine (Table 1). Overall, the hit compounds matched with three 
types of pharmacophore features: Two HBA (red), one HBD (green), 
and one PI area (blue).
We also analyzed the interactions of the entire list of hit compounds 
with DPP4 as the target and calculated the values of predicted ∆G and 
Ki using Autodock4. The parameters of the grid size box and the genetic 
algorithm runs used for molecular docking were set with an 80×80×80 
grid point with an interval of 0.375 Å, and 100, which is determined 
after verification that the RMSD value obtained was 0.17 Å.
Overall, at least nine compounds interacted with the residues in the 
DPP4 active sites; and eight of them have been predicted to be more 
selective toward DPP4 because they have interactions with the S1’ 
subsite (Table 2 and Fig. 2). Furthermore, hit compounds that had 
binding free energy <−6.5 kcal/mol may be more effective toward 
DPP4. These included alliin (−6.54), isoalliin (−6.81), l-noradrenaline 
(−7.12), Nb-demethylechitamine (−7.39), octopamine (−6.93), and 
subaphylline (−8.2).
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Table 2: Interactions between the hit compounds and the active sites of dipeptidyl peptidase-4
Residue/compounds Ali Iso His Nor The Mim MX1 MX2 MX5 Nde Oct Sub.
Tyr 48 v
Arg 125 v v v v v v v v v
Glu 205 v v v v v v v v v
Glu 206 v v v v v v v v v




Arg 429 v v
Tyr 456 v
Asp 545 v v
Val 546 v v
Tyr 547 v v v v v v v v v
Cys 551 v v
Ser 552 v v
Gln 553 v v
Lys 554 v v v v
Asp 556 v
Arg 560 v v v
Asn 562 v
Trp 563 v
Tyr 585 v v
Trp 627 v
Gly 628
Trp 629 v v v v
Ser 630 v v v v v v v v v v
Tyr 631 v v v v v v v v v
Val 656 v v
Trp 659 v v
Tyr 662 v v v v v v v v v
Tyr 666 v v v v v v v
Arg 669 v v
Asp 708 v
Asn 710 v v v v v v v v
His 740 v v v v
Tyr 752 v
Subsites (in color): S1 S2 S1’ S2’ S2 extensive
Ali: Alliin, Iso: Isoalliin, His: L-histidine, Nor: L-noradrenaline, The: L-theanine, Mim: Mimosine, MX1: Miraxanthin-I, MX2: Miraxanthin-II, MX5: Miraxanthin-V, Nde: Nb-
demethylechitamine, Ocp: Octopamine, Sub: Subaphylline. V: Hydrogen bond of hit compounds with interaction energy values <−6.50 kcal/mol (Fig. 3).
Fig. 2: (Left) Amino acid residues in the active site of dipeptidyl peptidase-4 (DPP4): (Right) Visualization of the interactions 
between the entire list of hit compounds with the S1 (orange), S2 (yellow), S1’ (green), S2’ (cyan), and S2 extensive (magenta) DPP4 
subsites
Nabeno et al. classified the DPP4 enzyme active sites into five binding 
sites (subsites), namely, S1, S2, S1’, S2’, and the site beyond S2 as S2 
extensive [10]. The S1 and S2 pocket sites are important interactions 
and are considered the basic binding mode in DPP4 activity. The S1 sites 
are the hydrophobic pocket consisting of the catalytic triad (Ser630, 
Asn710, and His 740) and the S2 sites are the ionic interaction sites with 
Glu205, Glu 206 [1], and Arg125 residues [13,14]. In addition, the S1 
pocket is also formed by highly hydrophobic residues such as Tyr631, 
Val656, Trp659, Tyr662, Tyr666, and Val711 [13,14]. Arulmozhiraja et al. 
revealed that the hydrophobicity is also related to enzyme activity [13]. 
Interactions through the S1 ‘(Tyr547) [2,13,14], S2’ (Trp629) [13], 
and S2 (Val207, Ser209, Arg358, Phe357) [2,13,16] pockets are also 
important and related to increased activity and selectivity.
As shown in Fig. 3 and Table 2, subaphylline interacted with residues 
on the active site of DPP4 with the highest binding free energy. Four 
strong hydrogen bonds were revealed, with a distance of 2.5 - 3.2 Å [17] 
on subaphylline, and the Glu205 (2.99), Glu206 (2.79) – S2 pockets, 
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Table 3: Comparison between drug-likeness and pharmacokinetic predictions of hit compounds using SwissADME
Parameter Alliin Isoalliin L-noradrenaline Nb-demethylechitamine Octopamine Subaphylline
Physicochemical properties
Formula C6H11NO3S C6H11NO3S C8H11NO3 C22H28N2O4 C8H11NO2 C14H20N2O3
Molecular weight (g/mol) 177.22 177.22 169.18 384.47 153.18 264.32
Num. heavy atoms 11 11 12 28 11 19
Num. arom. heavy atoms 0 0 6 6 6 6
Fraction Csp3 0.5 0.5 0.25 0.59 0.25 0.36
Num. rotatable bonds (NRotBs) 5 4 2 3 2 8
NHBA 4 4 4 5 3 4
NHBD 2 2 4 3 3 3
MR 43.24 43.24 44.13 111.84 42.11 74.79
TPSA [22] (Å²) 99.6 99.6 86.71 82.03 66.48 84.58
Lipophilicity (Log Po/w)
iLOGP [23] 0.55 0.88 0.87 3.02 1.01 2.37
XLOGP3 [12,24] −3.53 −3.45 −1.24 1.7 −0.9 1.03
WLOGP 0.2 0.55 −0.23 0.68 0.06 1.16
MLOGP [12,25,26] −2.88 −2.88 −0.25 2.1 0.33 0.88
SILICOS-IT [12] −1 −1.17 0.02 2.3 0.49 1.82
Consensus log Po/w [12] −1.33 −1.21 −0.17 1.87 0.2 1.45
Water solubility (Log S), Log S Scale: Insoluble <−10<poorly<−6<moderatly<−4<soluble<−2<very<0
ESOL [12,27] 1.62 1.5 −0.35 −2.98 −0.49 −1.83










Class Highly soluble Highly soluble Very soluble Soluble Very soluble Soluble
Ali [12,28] 2.02 1.94 −0.09 −2.59 −0.01 −2.4










Class Highly soluble Highly soluble Very soluble Soluble Very soluble Soluble
SILICOS-IT [12] −0.21 0.16 −0.76 −4.34 −1.32 −3.3










Class Soluble Soluble Soluble Moderately soluble Soluble Soluble
Pharmacokinetics
GI absorption [21] High High High High High High
BBB permeant [21] No No No No No No
P-gp substrate [12] No No No Yes No No
CYP1A2 inhibitor [12] No No No No No No
CYP2C19 inhibitor [12] No No No No No No
CYP2C9 inhibitor [12] No No No No No No
CYP2D6 inhibitor [12] No No No Yes No No
CYP3A4 inhibitor [12] No No No No No No
Drug-likeness
Lipinski (violation), MW ≤500, 
MLOGP ≤4.15, NHBA ≤10, 
NHBD ≤5
Yes Yes Yes Yes Yes Yes
Ghose [12,29] (violation), 160 
≤MW ≤480,−0.4 ≤MLOGP ≤5.6, 
40 ≤MR ≤130, 20 ≤num. atoms 
≤70
Yes Yes Yes Yes No (1), 
MW<160
Yes
Veber [12,30] (violation), 
TPSA≤131.6, NRotBs≤10
Yes Yes Yes Yes Yes Yes
Egan [12,31] (violation), 
WLOGP ≤5.88, TPSA ≤131.6
Yes Yes Yes Yes Yes Yes
Muegge [12,32] (violation), 
200 ≤MW ≤600, −2 ≤XLOGP ≤5, 
TPSA ≤150, NrotBs ≤15, num. 





No (2), MW 
<200, XLOGP3 
<−2
No (1), MW <200 Yes No (1), MW 
<200
Yes
Bioavailability score [33] 0.55 0.55 0.55 0.55 0.55 0.55
Medicinal chemistry
PAINS [18] (alert) 0 0 1 (Catechol A) 0 0 0
Brenk [19] (alert) 1 (Isolated 
alkenes)
0 2 (Catechol) 1 (Isolated alkenes) 0 1 (Michael 
acceptor 1)
Lead-likeness (violation), 




No (1), MW 
<200




Synthetic accessibility [34], from 
1 (very easy) to 10 (very difficult)
3.21 3.58 1.69 5.9 1.35 2.4
PAINS: Pan-assay interference compounds, MW: Molecular weight, TPSA: Topological polar surface area, NHBA: Num. H-bond acc., NHBD: Num. H-bond don., MR: Molar 
refractivity
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Tyr631 (3.14) – hydrophobic cavity of S1 pocket, Asp545 (3.0) and 
Lys554 (2.85) residues, and one weak hydrogen bond with a distance of 
3.0–4.0 Å [15] at the Trp662 (3.34) residue. Hydrophobic interactions 
also occurred between subaphylline with the S1 catalytic site (Ser630, 
Asn710, and His 740), S2 (Arg 125), Val546, and also at least at two 
hydrophobic pocket constituents (Tyr 547 and Trp629). Based on the 
results of molecular docking, we conclude that the compound has the 
potential to inhibit act as a DPP4 inhibitor.
a b
Fig. 3: Interaction of hit compounds with interaction energy values <−6.50 kcal/mol and the active site of dipeptidyl peptidase-4 (DPP4): 
Two dimensional visualization by Ligplot, the description referred to the web version;  ligand bond,  non-ligand bonds, 
 hydrogen bond, and its length,  non-ligand residues involved in hydrophobic contact(s),  corresponding atoms involved 
in hydrophobic contact(s) (a) subaphylline (b) Nb-demethylechitamine (c) L-Noradrenaline (d) octopamine (e) isoalliin (f) alliin
c d
e f
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residues in the S1 pocket, Arg125 and Glu206 in the S2 subsites, Tyr 
547 in the S1’ subsites, and Trp629 in the S2’ subsites. In accordance 
with the previous studies where Arulmozhiraja et al. revealed that 
the large-sized compounds that bind to hydrophobic pockets through 
hydrophobic interactions with lower interaction energy tend to have 
greater inhibitory activity than smaller compounds with higher binding 
energies [15]. Thus, we propose that Nb-demethylechitamine may also 
have potential DPP4 inhibitory activity.
In this study, l-noradrenaline emerged as a compound that could 
potentially inhibit DPP4 activity. L-noradrenaline has five strong 
hydrogen bonds, namely, at Arg125 (3.06) and Glu205 (2.64) in the S2 
subsites, along with Ser630 (3.09), Asn710 (3.00), Tyr631 (3.20), and 
Tyr666 (2.76) in the S1 subsites. In addition, hydrophobic interaction 
was observed at Glu 206 in the S2 subsites, Tyr 547 in the S1’ subsites, 
and Ser630 and Tyr662 in the S1 subsites.
As shown in Fig. 3 and 6, octopamine has a smaller size but has quite a 
lot of interaction with the active site of DPP4. It has six strong hydrogen 
bonds and two weak hydrogen bonds based on their distances, 
namely, Arg125 (2.87), Glu205 (2.71), and Glu206 (2.81 and 3.26) in 
the S2 subsites, Asn710 (3.13) and Tyr631 (2.79) in the S2 subsites, 
and Trp629 (3.26) in the S2’ subsites. Hydrophobic interactions only 
occur at three residues in the S1 subsites (Ser630 and Tyr662) and 
S1’ subsites (Tyr547); this is possible considering the small size of the 
compound.
For isoalliin, this compound has a small size but has many interactions 
with the active site of DPP4 (Table 2 and Figs. 3 and 6). Based on these 
Fig. 4: Illustration of BOILED-Egg and P-gp substrates/non-
subst rates for passive HIA and blood–brain barrier penetration 
A of hit compounds by SwissADME: Legend referred to the 
references [12,21]:  BBB (yellow or yolk regions),  HIA 
(elliptical region, Egan Egg),  P-gp substrates,  P-gp non-
substrates
Nb-demethylechitamine has two strong hydrogen bonds, as shown 
in Fig. 3, at Glu205 (2.72) and Asn710 (2.79). In addition, Nb-
demethylechitamine has ten hydrophobic interactions in the active 
site of DPP4, namely, Ser630, His 740, Tyr631, Tyr662, and Tyr666 
Fig. 5: (a-c) Pharmacophore features of the best model
a cb
Fig. 6: Three-dimensional visualization of interactions between the hit compounds with energy values <−6.50 kcal/mol and dipeptidyl 
peptidase-4 (a) subaphylline (b) Nb-demethylechitamine (c) L-Noradrenaline (d) octopamine (e) isoalliin (f) alliin
a b c
d e f
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findings, we believe this compound may be interesting to develop. As 
shown in Figs. 3 and 6, isoalliin has five strong hydrogen bonds and one 
weak hydrogen bond, namely, Arg125 (2.64) and Glu205 (2.67 and 
3.02) in the S2 subsites, as well as Ser630 (3.09), Asn710 (2.61), and 
His740 (3.34), which are the triad catalytic residues in the S1 subsite. In 
addition, there were at least seven hydrophobic interactions identified 
at Glu 206 in the S2 subsites, Val656 and Tyr 547 in the S1’ subsite, and 
the hydrophobic pocket constituent residues Tyr631, Val656, Trp659, 
Tyr662, and Tyr666.
Alllin has a molecular structure, type, and number of interactions almost 
the same as isoalliin. Alliin has six strong hydrogen bonds, namely, at 
Arg125 (2.70), Glu205 (2.77), and Glu 206 (2.71) in the S2 subsite, 
along with the triad catalytic residues Ser630 (3.20), Asn710 (2.69), 
and Tyr662 (3.11) in the S1 subsite. Hydrophobic interactions appear 
to occur at the S1’ subsite with Tyr 547 and the S1 hydrophobic pocket 
constituent residues Tyr631, Val656, Trp659, and Tyr666.
Bioavailability and medicinal chemistry predictions
Drug activity is strongly influenced by bioavailability, which is one 
factor that must be considered in the search and development of a new 
drug compound. There are several concepts related to the assessment 
of bioavailability, including drug-likeness and lead-likeness, in terms 
of in silico studies and pharmacokinetic parameters. In addition, an 
equally important assessment is the possibility that a compound can 
be synthesized. Therefore, we performed various calculations related 
to bioavailability and medical chemistry parameter predictions using 
SwissADME free web tools [9] (http://www.swissadme.ch).
We further determined that subaphylline was the most potent 
compound; this result is well correlated with our previous molecular 
docking assessments (∆G value and interaction with DPP4). This 
compound is in accordance with all the rules of the drug-likeness 
concept, which is a method developed to evaluate the relationship of the 
physicochemical properties of a compound using oral absorption and 
ADME parameters (Table 3), namely, MW (264.32 g/mol), consensus 
log Po/w (1.45), Number of H-bond acceptors (4), Number of H-bond 
donors (3), MR (74.79), num. atoms (39), topological polar surface area 
(TPSA) (84.58 Å²), NRotBs (8), num. ring (1), and num. heteroatoms 
(5). This compound is also predicted to have good solubility in water 
(Table 3), thus it is preferred to be developed. For pharmacokinetic 
parameters, the BOILED-Egg prediction model (Fig. 4) shown that 
this compound has good absorption in the gastrointestinal (GI) tract 
and does not penetrate the blood-brain barrier (elliptical region, Egan 
egg). Further predictions demonstrated that subaphylline is not likely 
a P-gp substrate, but rather inhibits CYP2D6. For the identification 
of problematic fragments, pan-assay interference compounds 
(PAINS) [18] predictions shown that the compound does not contain 
fragments that have the potential to give false-positive results; however, 
Brenk [19] predictions showed that the compound contains a Michael 
acceptor (C=C C=O) that is reactive and potentially toxic [19,20]; thus 
it is essential to evaluate the compound with further testing. Finally, 
predictions regarding the accessibility of these compounds to be 
synthesized indicated that the compounds would likely be easy to 
synthesize (synthetic accessibility scale, 2.4). Overall, subaphylline has 
good oral bioavailability, is suitable for synthesis, and meets the criteria 
as a lead compound (lead-likeness; only one violation, NRotBs >7).
As shown in Table 3 and Fig. 4, similar to the predictions for subaphylline, 
Nb-demethylechitamine was also considered in accordance with all 
the rules of the drug-likeness concept, namely, MW (384.47 g/mol), 
consensus log Po/w (1.87), NHBA (5), NHBD (3), MR (111.84), num. 
atoms (54), TPSA (84.58 Å²), NRotBs (3), num. ring (3), and num. 
heteroatoms (6). Nb-demethylechitamine has good solubility in water, 
good absorption in the GI tract and does not penetrate the blood-brain 
barrier. In addition, it is a P-gp substrate and does not inhibit cytochrome 
P450. For the prediction of fragments, PAINS predictions shown that 
the compound does not contain fragments that have the potential to 
give false positive results, but Brenk predictions demonstrated that 
the compound contains isolated alkenes (C=C C – Csp3or H) that may 
be reactive and potentially toxic [19]. However, predictions regarding 
the accessibility of these compounds to be synthesized show that 
compounds are moderately synthesized (synthetic accessibility scale, 
5.9). Overall, Nb-demethylechitamine has good oral bioavailability, 
suitable to be synthesized and meets the criteria as a lead compound 
(lead-likeness; only one violation, MW >350).
For isoalliin and alliin, overall, they met the rules of the drug-likeness 
concept from Lipinski et al., Ghose et al., Veber et al., Egan et al., and 
Muegge et al. (with only two violations; MW <200, XLOGP3 <−2). They 
have similar physicochemical properties; MW (177.22 g/mol), consensus 
log Po/w (−1.21 and −1.33), NHBA (4), NHBD (2), MR (43.24), num. 
atoms (22), TPSA (99.6 Å²), NRotBs (4 and 5), num. ring (0), and num. 
heteroatoms (5). Isoalliin and alliin are highly soluble in water, have 
good absorption in the GI tract, and do not penetrate the blood-brain 
barrier. They may be P-gp substrates but do not inhibit cytochrome 
P450. For the prediction of problematic fragments, isoalliin does not 
have structural problems (no alert in the PAINS and Brenk predictions), 
but alliin showed that the compound contains isolated alkenes (C=C C–
Csp3or H) that may be reactive and potentially toxic [19]. However, for the 
accessibility of these compounds to be synthesized, our results indicated 
that both compounds can be synthesized (synthetic accessibility scale, 
3.58 and 3.21). Overall, isoalliin and alliin have good oral bioavailability, 
are suitable for synthesis, and meet the criteria as lead compounds (lead-
likeness; only one violation, MW <200), Table 3 and Fig. 4.
Similar to the other compounds, as shown in Table 3 and Fig. 6, 
octopamine meets the rules of the drug-likeness concept from Lipinski 
et al., Ghose et al. (with only one violation; MW <160), Veber et al., Egan 
et al., and Muegge et al. (with only one violation; MW <200). Octopamine 
has physicochemical properties of MW (153.18 g/mol), consensus 
log Po/w (0.2), NHBA (3), NHBD (3), MR (42.11), num. atoms (22), 
TPSA (66.48 Å²), NRotBs (2), num. ring (1), and num. heteroatoms (3). 
Octopamine is very soluble in water, has good absorption in the GI tract, 
and does not penetrate the blood–brain barrier. It is not a likely a P-gp 
substrate and does not inhibit cytochrome P450. Overall, octopamine is 
considered a chemically good compound; it does not have problematic 
fragments (no alert in the PAINS and Brenk predictions) and has excellent 
accessibility to be synthesized (synthetic accessibility scale, 1.35). In 
addition, octopamine has good oral bioavailability and meets the criteria 
as a lead compound (lead-likeness; only one violation, MW <200).
For l-noradrenaline, we do not discuss the results of bioavailability 
and medicinal chemistry predictions because this compound is 
already available as a drug. Further development can be carried out 
with or without structural modification related to the possibility that 
l-noradrenaline can inhibit DPP4 based on the results of this study.
CONCLUSION
Based on the results of the in silico screening we performed, we conclude 
that the six hits obtained, namely, l-noradrenaline, octopamine, 
Nb-demethylechitamine, alliin, isoalliin, and subaphylline have the 
potential to be further developed or investigated related to their 
activities as inhibitors of DPP4. Moreover, combined with the other 
analyses that we have performed with regard to molecular docking, 
bioavailability, and medicinal chemistry predictions, we propose that 
subaphylline is the most recommended compound for further studies 
focused on molecular dynamics, in vitro and in vivo experiments, and 
structural modification.
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